title: [Prognostic factors of upper tract urothelial carcinoma].
abstract: BACKGROUND
  Upper urinary tract urothelial carcinoma (UTUC) is a rare disease. Thus, little evidence-based data are available to guide clinical decision-making. The aim of the study was to provide an overview of the currently available prognostic factors for UTUC.
  
  
  METHODS
  A systematic literature search was conducted using the PubMed databases to identify original articles regarding prognostic factors in patients with UTUC.
  
  
  RESULTS
  We divided the prognostic factors for UTUC in four different categories: clinical factors, preoperative characteristics, intraoperative/surgical factors and postoperative/pathologic factors. Prognostic factors described in order of importance are: tumor stage and grade, lymph node involvement, a concomitant cis, age at the diagnostic, lymphovascular invasion, tumor architecture and necrosis, tumor location and multifocality, gender. The impact of obesity, smoking and other comorbidities (ECOG, ASA) on outcomes has been recently reported but needs to be validated. The endoscopic approach of distal ureter management during radical nephroureterectomy has been shown to be at higher risk of bladder recurrence.
  
  
  CONCLUSIONS
  The incorporation of such prognosticators into clinical prediction models might help to guide decision-making with regard to timing of surveillance, type of treatment, performance of lymphadenectomy, and consideration of neoadjuvant or adjuvant systemic therapies.
authors.affiliation: Services d'urologie et d'anatomopathologie, faculté de médecine Paris Descartes, université Paris V, hôpital Cochin-Port-Royal, Assistance publique-Hôpitaux de Paris, 75639 Paris cedex 14, France.
authors.forename: V
authors.initials: V
authors.lastname: Elalouf
authors.forename: J
authors.initials: J
authors.lastname: Klap
authors.forename: N-B
authors.initials: NB
authors.lastname: Delongchamps
authors.forename: S
authors.initials: S
authors.lastname: Conquy
authors.forename: M
authors.initials: M
authors.lastname: Sibony
authors.forename: D
authors.initials: D
authors.lastname: Saighi
authors.forename: M
authors.initials: M
authors.lastname: Peyromaure
authors.forename: T
authors.initials: T
authors.lastname: Flam
authors.forename: M
authors.initials: M
authors.lastname: Zerbib
authors.forename: E
authors.initials: E
authors.lastname: Xylinas
mesh_terms: D017677:Age Distribution; D015992:Body Mass Index; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D019317:Evidence-Based Medicine; D006801:Humans; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D009367:Neoplasm Staging; D009765:Obesity / Q000150:complications; D011379:Prognosis; D012307:Risk Factors; D017678:Sex Distribution; D012907:Smoking / Q000009:adverse effects; D014516:Ureteral Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy
keywords: Prognostic; Pronostic; Recurrence; Récidive; Survie; Survival; Tumeur de la voie excrétrice urinaire supérieure; Upper tract urothelial carcinoma